Physician profile
Diane E Calderon
NPI 1093780827
$714.74
in general payments reported to CMS, 2019-2025
10 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $19.40 · 2022: $80.36 · 2023: $62.68 · 2024: $290 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160.34 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $146.10 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $119.16 | 2019 | |
| Alcon Vision LLC | $106.60 | 2022-2025 | Tryptyr |
| Bausch & Lomb Americas INC. | $47.62 | 2023-2025 | Miebo |
| Sun Pharmaceutical Industries INC. | $38.06 | 2023 | Cequa |
| Harrow Eye, LLC | $33.07 | 2025 | Vevye |
| Glaukos Corporation | $28.38 | 2025 | Photrexa Viscous and Photrexa |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $16.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.